Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-14
1996-03-12
Brust, Joseph Paul
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548539, 435121, 4352541, A61K 3140, C07D20724
Patent
active
054986273
ABSTRACT:
This invention provides a novel compound TAN-1813 having farnesyltransferase-inhibitory, cell growth-inhibitory, and anti-tumor activities; its production; farnesyltransferase-inhibiting agent; anti-tumor agent; pharmaceutical composition comprising a compound TAN-1813; and a novel microorganism capable of producing said compound.
REFERENCES:
James, et al., "Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells", Science, vol. 260, 25, Jun. 1993 pp. 1937-1942.
Chemical Abstracts, vol. 121, No. 13, 1994, Columbus, Ohio, US; Abstract No. 157425g, (Ishizuka et al).
Chemical Abstracts, vol. 122, No. 5, 1995, Columbus, Ohio, US; Abstract No. 54155k, (Tamamura et al).
Bos: "ras Oncogenes in Human Cancer: A Review"; Cancer Research 49, pp. 4682-4689, (Sep. 1, 1989).
Willumsen et al, "The p21 ras C-terminus is required for transformation and membrane association"; Nature vol. 310 16 (Aug. 1984), pp. 583-586.
Gibbs, et al, "Zenopus oocyte germinal-vesicle breakdown induced by [Val.sup.12 ] Ras is inhibited by a cytosol-localized Ras mutant"; Proc. Natl. Acad. Sci. USA, vol. 86, pp. 6630-6634, (Sep. 1989).
Clarke, "Protein isoprenylation and methylation at carboxyl-terminal cysteine residues", Annu. Rev. Biochem. (1992) 61 pp. 355-386.
Schafer, et al, "Protein prenylation: genes, enzymes, targets, and functions", Annu. Rev. Genet. (1992), 30 pp. 209-237.
Reiss, et al, "Inhibition of purified p21.sup.ras farnesyl:protein transferase by cys-AAX tetrapeptides"; Cell, vol. 62, pp. 81-88, Jul. 13, 1990.
Tamanoi, "Inhibitors of ras farneslyltransferases", TIBS 18, (Sep. 1993), pp. 349-353.
Miura, et al, "Inhibition of protein prenylation by patulin", FEBS 12137, vol. 318, No. 1, pp. 88-90, (Feb. 1993).
Kohl et al, "selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor", Science, vol. 260, (25 Jun. 1993) pp. 1934-1937.
Kothapalli et al, "Farnesylamine: an inhibitor of farnesylation and growth of 35 U.S.C. ras-transformed cells", Lipids, vol. 28, No. 11 (1993), pp. 969-973.
Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays", Journal of Immunological Methods, 65, (1983) pp. 55-63.
Ueno et al., "Delaminomycins, Novel Nonpeptide Extracellular Matrix Receptor Antagonist and A New Class of Potent Immunomodulator", Journal of Antibiotics, vol. 46, No. 6, pp. 979-984, Jun. 1993.
Hida Tsuneaki
Ishii Takafumi
Nozaki Yukimasa
Ootsu Koichiro
Brust Joseph Paul
Takeda Chemical Industries Ltd.
LandOfFree
Octahydro-2-naphthalenecarboxylic acid derivative, its productio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Octahydro-2-naphthalenecarboxylic acid derivative, its productio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydro-2-naphthalenecarboxylic acid derivative, its productio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100199